Lymphocyte/NN
glucocorticoid/NN
receptor/NN
:/:
predictor/NN
of/IN
sertraline/NN
response/NN
in/IN
adolescent/JJ
major/JJ
depressive/JJ
disorder/NN
(/(
MDD/NN
)/)
./.

Major/JJ
depressive/JJ
disorder/NN
(/(
MDD/NN
)/)
in/IN
adolescents/NNS
demonstrates/VBZ
resistance/NN
to/TO
tricyclic/JJ
antidepressants/NNS
and/CC
absence/NN
of/IN
hypercortisolemia/NN
./.
=====
The/DT
efficacy/NN
of/IN
serotonin/NN
reuptake/NN
inhibitors/NNS
(/(
SRIs/NNS
)/)
is/VBZ
uncertain/JJ
,/,
and/CC
response/NN
predictors/NNS
are/VBP
unavailable/JJ
./.
=====
Abnormal/JJ
fast/JJ
feedback/NN
and/CC
negative/JJ
feedback/NN
of/IN
the/DT
hypothalamic-pituitary-adrenal/JJ
axis/NN
implicates/VBZ
a/DT
dampened/JJ
limbic-hippocampal/JJ
glucocorticoid/NN
type/NN
II/CD
receptor/NN
(/(
GCII/NN
)/)
./.
=====
We/PRP
hypothesized/VBD
that/IN
lymphocyte/NN
GCII/NN
is/VBZ
altered/VBN
in/IN
adolescent/JJ
MDD/NN
and/CC
could/MD
serve/VB
as/IN
a/DT
marker/NN
for/IN
response/NN
to/TO
SRIs/NNS
./.
=====
In/IN
an/DT
open-label/JJ
study/NN
,/,
adolescents/NNS
(/(
n/NN
=/JJ
20/CD
)/)
meeting/VBG
DSM-III-R/NN
criteria/NNS
for/IN
MDD/NN
showed/VBD
baseline/NN
lymphocyte/NN
GCII/NN
sites/NNS
per/IN
cell/NN
(/(
sites/cell/NNS
)/)
values/NNS
of/IN
793/CD
+/-/CC
106/CD
versus/CC
2/CD
,/,
563/CD
+/-/CC
499/CD
(/(
+/-/CC
SEM/NN
)/)
for/IN
matched/VBN
controls/NNS
(/(
n/NN
=/JJ
18/CD
)/)
(/(
t/NN
=/JJ
3.5/CD
;/:
df/NN
=/JJ
36/CD
;/:
p/NN
</JJR
.001/CD
)/)
./.
=====
GCII/NN
was/VBD
bimodally/RB
distributed/VBN
,/,
with/IN
SRI/NN
responders/NNS
differing/VBG
from/IN
nonresponders/NNS
(/(
t/NN
=/JJ
3.9/CD
;/:
df/NN
=/JJ
14/CD
;/:
p/NN
</JJR
.001/CD
)/)
./.
=====
GCII/NN
accurately/RB
classified/VBD
90/CD
percent/NN
of/IN
sertraline/NN
responders/NNS
and/CC
80/CD
percent/NN
of/IN
nonresponders/NNS
./.
=====
Only/RB
SRI/NN
responders/NNS
showed/VBD
GCII/NN
sites/cell/NNS
upregulated/VBN
after/IN
6/CD
weeks/NNS
of/IN
treatment/NN
(/(
t/NN
=/JJ
2.1/CD
,/,
df/NN
=/JJ
10/CD
;/:
p/NN
</JJR
.05/CD
)/)
./.